The U.S. Food and Drug Administration has approved Auvelity, a combination of dextromethorphan and bupropion, for treating agitation associated with Alzheimer's disease. According to the Alzheimer's Association, it is the only FDA-approved treatment for Alzheimer's-related agitation that is not classified as an antipsychotic.
That distinction is the heart of the news. Agitation - restlessness, aggression, distress that can escalate without warning - is one of the symptoms families find hardest to manage, and until now the approved pharmacological options came from a drug class carrying significant risks. "For too long, people living with Alzheimer's disease agitation and their families have had limited options, and the options that existed came with significant risks," said Joanne Pike, president and CEO of the Alzheimer's Association, who described the approval as an important new tool that works through a different mechanism than antipsychotic medications.
The drug, previously known as AXS-05, was developed by Axsome Therapeutics. The company said that alongside the commercial launch it will introduce a patient support program, Auvelity OnMySide, offering resources such as financial aid and insurance assistance to eligible patients - a practical consideration, given how often cost and coverage decide whether a newly approved medication actually reaches the people it was approved for.
For caregivers and clinicians, the significance lies less in a new cure than in a new choice. Agitation shapes daily life for people with Alzheimer's and for those caring for them, and having an option outside the antipsychotic class gives prescribers room to weigh benefits and risks differently than they could before.